EVO (Evotec SE) Payments of Debt: $-98.8 Mil (TTM As of Mar. 2026)


EVO Evotec SE EVO
63 GF Score
Price $2.80
GF Value $4.40
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Evotec SE Payments of Debt?

Evotec SE EVO -1.94% 63 Payments of Debt is $-98.8 Mil as of Mar. 2026. GuruFocus rates EVO with a GF Score™ of 63/100 and a GF Value™ of $4.40 (Possible Value Trap). The stock has 5 warning signs investors should review.

Evotec SE's Payments of Debt for the three months ended in Mar. 2026 was $-22.1 Mil.

Evotec SE's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-98.8 Mil.

Evotec SE Payments of Debt Related Terms

Evotec SE Payments of Debt Historical Data

* Premium members only.

The historical data trend for Evotec SE's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE Payments of Debt Chart

Evotec SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -41.45 -56.26 -147.58 -160.18 -85.92

Evotec SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.36 -13.34 -12.06 -51.29 -22.07
EVO
63GF Score
Evotec SE EVO
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-98.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-98.8 Mil mean?
Evotec SE (EVO) has a Payments of Debt of $-98.8 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Evotec SE and its competitors.
Is Evotec SE's Payments of Debt too high?
Evotec SE's current Payments of Debt is $-98.8 Mil. Overall, Evotec SE has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Payments of Debt compare to ZTS and UTHR?
Evotec SE's Payments of Debt of $-98.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Evotec SE and its competitors. Evotec SE's current Payments of Debt is $-98.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.40, compared to a current price of $2.80 — trading 36.5% below its estimated fair value. The current Payments of Debt is $-98.8 Mil. Evotec SE's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Evotec SE (EVO), the current Payments of Debt is $-98.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (EVO) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of $2.80 is trading 36.5% below its estimated GF Value™ of $4.40. GuruFocus considers Evotec SE to be Possible Value Trap.

Key valuation signals for EVO:

  • Payments of Debt: $-98.8 Mil
  • GF Value™: $4.40 vs. price of $2.80 (36.5% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
63GF Score

Get the complete analysis for EVO

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.80
Price
$4.40
GF Value